# LKtime Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lktime-biotech

- Industry: Biotechnology
- Headquarters: Zhongshan, China
- Total disclosed funding: $26M
- Latest round: Series B (Jul 2, 2024)
- Investors on record: 3

## About

Based in Zhongshan, China, and founded in 2021, LKtime Biotech is a CDMO service provider for biological products, committed to providing users with relevant biotechnology products and services. The company has set up a research and development center and two production centers. In Dcember 2021, it closed a strategic investment from Fuho Capital. In July 2024, LKtime Biotech raised CNY 190 million in series B funding led by new investor Zhongshan Venture Capital.

LKtime Biotech focuses on providing macromolecular CDMO (Contract Development and Manufacturing Organization) services from DNA to IND (Investigational New Drug) or BLA (Biologics Licence Application) for innovative biopharmaceutical companies. The company has mammalian cell (such as CHO and 293 cell) platforms and microbial (such as yeast, E. coli) platforms. It has operated more than 70 development and production projects of macromolecular drug (such as antibodies, vaccines, recombinant proteins, peptides, etc.)

The company generates revenue by providing macromolecular CDMO services.

The company will further expand its commercial production base, upgrade its innovative R&D center and pilot base, and expand its production capacity.

## Funding rounds

- Series B, Jul 2, 2024, $26M — Fuho Capital, Zhongshan Venture Capital, Xiwan Investment

## Investors

- Fuho Capital (https://capitalatlas.ai/funds/fuho-capital) — Series B
- Zhongshan Venture Capital (https://capitalatlas.ai/funds/zhongshan-venture-capital) — Series B
- Xiwan Investment — Series B